{"name":"InterMune","slug":"intermune","ticker":"","exchange":"","domain":"","description":"InterMune was a biotechnology company focused on the research and development of therapies for serious and life-threatening diseases. The company's primary focus was on pulmonary fibrosis and other rare lung diseases, with a portfolio that included several investigational drugs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":70339000,"revenueGrowth":168.7,"grossMargin":0,"rdSpend":113506000,"netIncome":-219568000,"cash":462633000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Actimmune Registry","genericName":"Actimmune Registry","slug":"actimmune-registry","indication":"Severe malignant osteopetrosis","status":"phase_2"}]}],"pipeline":[{"name":"Actimmune Registry","genericName":"Actimmune Registry","slug":"actimmune-registry","phase":"phase_2","mechanism":"Interferon gamma-1b is a recombinant form of the human interferon gamma protein that helps to stimulate the immune system to fight infections and diseases.","indications":["Severe malignant osteopetrosis","Severe chronic granulomatous disease","Severe congenital neutropenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQcFFYOHMwZ2FpMzk0WkxCdkd6MXdueEozZ2NxczZyZUpWM212LXJTMGhHeXNZci1INUJaVTdESW5OOEZvTEV1QlN3a18wODNtcDVKMnRXck82NjZIZ2hYamgxUmNHMzFHNU9UYndHVlFmVjBoSkxCZ3BfcnRUM3QwX2U5Q1BOa3M?oc=5","date":"2025-02-11","type":"pipeline","source":"pharmaphorum","summary":"Ten years on, Roche jettisons InterMune and Esbriet in US - pharmaphorum","headline":"Ten years on, Roche jettisons InterMune and Esbriet in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5aYWN4Nnh3QlYzMm9vd24yYnRuUDJUclRYNUkyVUFHSmtFWEIySlFxVV9PR0lvS3hXdGFfcHcwVW5PN1hmcG5YUXF1VGxQeGZSMDhDNWRZZnZ3REhZR2w1Ukl3WC1sMWE1U2o3SlNqQm9aYjN1MlpHMW9mMGw?oc=5","date":"2025-02-11","type":"deal","source":"The Pharma Letter","summary":"Legacy Pharma buys Roche’s InterMune unit - The Pharma Letter","headline":"Legacy Pharma buys Roche’s InterMune unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBUM2dhWHFqNFEwVW5hXzR3ZGNnRjBzNGE2RWdXVG5wUVVJZ0hiRGNvNnNmS2RUMmlfdWM4TzFJQWxFTDd0djRZV1JIWEFVOXdTSjM0?oc=5","date":"2025-02-10","type":"patent","source":"FirstWord Pharma","summary":"Roche offloads Esbriet as generics dent sales - FirstWord Pharma","headline":"Roche offloads Esbriet as generics dent sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQcHhTTGI4MlQ1ZDhvVDdNZlBJOVAwRHRYdDhBdU0wbDhIS3ZaNkx0MXYzeG01eV9rd1JkVEVfb3dobU5YeWF2V2h4NXNkRmhnLVNjVDFFRjFoTnNSR01JT1BzOW5RNVZ3ejFINUptMmJGYm5XemY4R3EwOVVrRl9WdXBpeThXNEF3cU1CMVEzMGRjN2dQVmo1c3NNS1VoNEpwRHc?oc=5","date":"2025-02-10","type":"trial","source":"Endpoints News","summary":"Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma - Endpoints News","headline":"Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBYX3FkVkNvb2NxSkRneW9wZTFPcm16b1A1QlFZVzhYdkhQeW9Fbm1VZGh0WldDY09Ub3lLNjRVOFlRa1I5U1BCMGdBRzhHSnZi?oc=5","date":"2025-02-06","type":"pipeline","source":"PR.com","summary":"Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group - PR.com","headline":"Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Me","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNRGNvdVctaFFqME5fVGduS2FNeDZJc05fS1p1M0FTZUN0Q1hSUlRla0FUcWJxSndrbkVUSlc1alhVamFBdHRkamZ1MXFHQ2VmS1VDODR3bDQtUDRjNmtpMjN5Y1NKeGtJRFpaTVUtaURWcl9ZYWMxbEZ5WHZpMkFQTFJKbWpkM0ZQUkdFYXd2YlgzMmhLcjdyRDEyZ1htTEJQdWlOd1RSRHhhY3U3dVhoZVNwX1lZOVg5bHc?oc=5","date":"2023-12-25","type":"deal","source":"respiratory-therapy.com","summary":"Roche’s $8.3B Buyout of InterMune to Strengthen Respiratory Portfolio - respiratory-therapy.com","headline":"Roche’s $8.3B Buyout of InterMune to Strengthen Respiratory Portfolio - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQbDFFUWJEWlJtbmNkbVBOM1d5S2JiZ2QyV3ZHcHhwM3BubDg2RG11eFBKbkdOZUpkSzlKaEZuczV0UkEwV0cxWUR1Mkk4SjRxcHFCd21reTVzcUdwNnBYcHdNZ0VSb0FuNS14OXVMMG9GRUlkVzBaYV9vaEhTVmtnaGliaFJ1OVZQZjZpVU9OWm1wa2hGeGt2RENFSnB5UkMxSDFV?oc=5","date":"2015-01-08","type":"pipeline","source":"BioSpace","summary":"After $8.3 Billion Sale to Roche, InterMune, Inc. Chief Jumps to Venture Capital - BioSpace","headline":"After $8.3 Billion Sale to Roche, InterMune, Inc. Chief Jumps to Venture Capital","sentiment":"neutral"},{"date":"2014-10-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE41S2JxeDVDWW5Nc1ZJeHFmdXRWY3BzNnRFT3ltdHEwcXR5c0c4amVjNFJOXzNYTXNiM01kV0ZNNnV5Z0s0eGE4bHQ4NnRzNW1VSi0zX2t2SVR2cDIwMUgwSHdYUVR6TkZqVjIxTg?oc=5","date":"2014-08-28","type":"deal","source":"C&EN","summary":"Roche To Buy Intermune - C&EN","headline":"Roche To Buy Intermune - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOSmpxUzhMdFZ5XzNNaEhZWFVrdnpabExBa0RwOGxZVmxocFNNVXdFR05vR0RRSVcyejBwWTJpOF9qaVNSTEpBOUxzMlZxcHVYUUpoYk00cmUxdGNQVVI4aExJeWpqcHNZd1RqR0JwOXF2UmdZVGJjR3BNb1E2akk3dnV6cmZmRWpfY2g3NWUwNFI4ZE9HVHVWQ2hQZF9QeWlTd3I5RlB3SnBMRS1xenA4QkNoN0QzUzJDczVoNTJXNEpLLWFkdlFWeVZXTHJkVnpRemc?oc=5","date":"2014-08-25","type":"deal","source":"Reuters","summary":"Roche to buy U.S. biotech firm InterMune for $8.3 billion - Reuters","headline":"Roche to buy U.S. biotech firm InterMune for $8.3 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPXy1BTm5xcWRrLUdJZG04M29PV1NHMUlLbVpRTnRVUUhaZTk0UDZVVFY1UUJhZVpNMi1oWndYbXA3VUtwWmo2LWZNNkdPbGt4Qjhtb1dmODdkVmlxUHl0dHgwd2M3bzE4UVhSdjVhMmduVVBJY2Q1UDVrSVZLNlhNOEZjSFZLY05IQkxfR2JyZ0taTmEwUTNIUWVBS1hRU2g0UmpTXzZNellrMXlSc3c?oc=5","date":"2014-08-25","type":"pipeline","source":"Fortune","summary":"Roche paying $8.3 billion for InterMune and its ‘breakthrough’ respiratory drug - Fortune","headline":"Roche paying $8.3 billion for InterMune and its ‘breakthrough’ respiratory drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFAzVVI1d2pWX3NET0RjY29IclF2ZVpYS0RFNHpfZTR1Z0k0QVprdW5lcHJWbnhOVUdFOWplaFdDSzhKbUZPdE5OZjB4TDFWcURXZWgxaNIBWkFVX3lxTE82M3FTa240cjdtODRLdGE1Rll1QlBaQUk3azh2bWhMX1UzbmdKX3JSMGU3b3BydVNJdmEwRV9FUm1Vdk9xUUNPcF9aMHVLZVVKRXp5SHpBQXNQdw?oc=5","date":"2014-08-24","type":"deal","source":"BBC","summary":"Roche buys US biotech firm InterMune for £5bn - BBC","headline":"Roche buys US biotech firm InterMune for £5bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxON1lOVy1nMEF6QUxWclVkVzRxOEtsTVNDdDU4Y282a3pKQllTLVhWU1UteVVlLWFjMy1tVlVIaEZqeXZHY1dHRVBZcS1jTjJmbzE2WnE4bWZSbk9Ua2NZSTF0d1ZPXzJoSlRpOGZRelJnNXltbXFhc0hnUGlCSlJBdFRDTGpGVUJkOHc?oc=5","date":"2014-08-24","type":"deal","source":"WSJ","summary":"Roche to Acquire InterMune for $8.3 Billion - WSJ","headline":"Roche to Acquire InterMune for $8.3 Billion","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":70339000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":70339000,"period":"2013-12-31"},{"value":26174000,"period":"2012-12-31"},{"value":26174000,"period":"2012-12-31"},{"value":8222000,"period":"2012-12-31"},{"value":17952000,"period":"2012-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":113506000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-219568000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":462633000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}